Journal article
Lifetime cost of HIV management in Australia: an economic model
M Lim, A Devine, RT Gray, JA Kwon, JL Hutchinson, JJ Ong
Sexual Health | CSIRO PUBLISHING | Published : 2022
DOI: 10.1071/SH21250
Open access
Abstract
Background. Antiretroviral therapy (ART) for HIV has significantly reduced morbidity and mortality, but the drugs can be expensive. This study aimed to estimate the lifetime cost of HIV management from the Australian healthcare perspective. Methods. A Markov cohort model, consisting of 21 health states based on CD4 count and line of ART, simulated disease progression over the lifetime of persons living with HIV. We reported costs using 2019 Australian dollars (A$) at a discount rate of 3.5% per annum. One-way sensitivity analysis was used to assess the impact of model inputs, and probabilistic sensitivity analyses were conducted to calculate the 95% confidence intervals for the lifetime ..
View full abstractGrants
Awarded by University of New South Wales
Funding Acknowledgements
Jason J. Ong is supported by an Australian National Health and Medical Research Council (NHMRC) Emerging Leader Investigator Grant (GNT1193955). The funding body did not influence the research or decision to publish. The Kirby Institute is funded by the Australian Government Department of Health, and is affiliated with the Faculty of Medicine, UNSW Sydney, Australia.